50 Bioprinting · Material Extrusion companies in the additive manufacturing ecosystem tracked by AMPulse. Browse profiles, funding rounds, and technology details.
Updated
Material Extrusion (MEX) is Material Extrusion (Fused Deposition Modeling, FDM; Fused Filament Fabrication, FFF) — a heated thermoplastic filament is extruded through a nozzle, building parts layer by layer. AMPulse tracks 50 companies using Material Extrusion as a core technology, ranked below by total funding raised.
Typical materials: PLA, PETG, ABS, PEEK, PEI, nylon, polycarbonate, composites. Common applications: prototyping, jigs and fixtures, end-use polymer parts, consumer products, education.
Material Extrusion — sold as Fused Deposition Modeling (FDM, Stratasys trademark) and Fused Filament Fabrication (FFF, the open-source equivalent) — is the most widely deployed AM process by unit count, with millions of desktop and industrial machines globally. The process extrudes thermoplastic filament through a heated nozzle, depositing molten material along toolpaths to build parts layer by layer. MEX's appeal is breadth: machines range from $200 desktop printers used in classrooms to $500K industrial systems running PEEK and ULTEM for aerospace tooling. The technology occupies three distinct markets that share little: education and consumer (Bambu Lab, Prusa, Creality), professional prototyping (Ultimaker, MakerBot, Markforged), and industrial production (Stratasys F900, 9085-series). Bambu Lab's 2022 entry — sub-$1,500 systems with industrial-grade speed and reliability — disrupted the prosumer segment more thoroughly than any single product launch in AM history.
Stratasys (FDM trademark holder) dominates the industrial segment with F-series (F123, F770, F900) systems running engineering thermoplastics. Markforged combines FDM with continuous fiber reinforcement (carbon fiber, Kevlar, fiberglass) for end-use composite parts. Ultimaker (now part of the merged Ultimaker-MakerBot entity) leads professional desktop. The consumer and prosumer market saw a watershed reordering: Bambu Lab (X1, P1, A1 series) overtook Prusa, Creality, and Anycubic in 2023 by combining AMS multi-material, automatic calibration, and Klipper-derived speed. Open-source ecosystems (RepRap descendants, Voron community builds, Klipper firmware) supply most of the consumer mid-tier through Aliexpress-grade hardware. Filament suppliers (Polymaker, Prusament, MatterHackers) capture significant margin downstream.
Three forces are reshaping MEX. First, Bambu Lab's commercial speed advantage is forcing legacy desktop OEMs (Prusa, Ultimaker, MakerBot) into either price competition or premium repositioning. Second, large-format FDM (BigRep, 3D Systems Roboze, Caracol) is displacing CNC machining for tooling, jigs, and end-use polymer parts — particularly with PEEK, PEI, and continuous-fiber materials. Third, software is consolidating: Bambu Studio, OrcaSlicer, and Cura now define UX standards, while industrial workflow tools (Stratasys GrabCAD, Dyndrite for slicing) target high-end production. The continuous-fiber segment (Markforged, Anisoprint, Continuous Composites) is the most differentiated growth area.
MEX continues bifurcating. The bottom — desktop consumer — moves toward complete commoditization as Bambu Lab's price-performance bar normalizes. The top — industrial high-temperature thermoplastics, continuous-fiber composites, large-format — captures the production-grade market. The middle, currently held by Ultimaker, Markforged, and similar prosumer-pro segments, faces compression from both ends. Material innovation (recycled polymers, bio-based filaments, conductive composites) is increasingly the competitive differentiator at all tiers.
Provides cells, media, and reagents integrated into 3D bioprinting workflows for advanced cell culture and tissue constructs, enabling pharmaceutical and biotech research.
Produces cultivated meat using bioprinting and cellular agriculture technology, creating real animal meat from cells without slaughtering animals.
Develops in-space additive manufacturing systems and facilities for microgravity environments, enabling on-orbit production of tools, structures, and biological tissues to reduce Earth-launch dependency and costs.
Develops the CHIMERA 5-in-1 biofabrication platform for 4D bioprinting of human tissues with embedded biosensors and bioelectronics, enabling high-throughput production for regenerative medicine and drug testing.
Develops vertically integrated 3D bioprinting platforms and materials for manufacturing whole replacement organs.
Develops innovative 3D bioprinting systems including state-of-the-art bioprinters and bioinks used for printing human tissues and organs.
Aspect Biosystems develops bioprinted tissue therapeutics using AI-powered bioprinting technology, computational design tools, advanced biomaterials, and therapeutic cells.
Provides in-house, patient-specific 3D printing services for surgical planning, anatomical models, and medical devices, reducing surgical time by up to 25% and improving outcomes.
A pioneering food-technology company that produces 'New-Meat'—plant-based meat products, including the world's first commercial-scale 3D-printed whole-cuts, designed to replicate the sensory experience of animal meat.
Develops cultivated beef steaks using 3D bioprinting and cellular agriculture technology, producing slaughter-free meat with the taste, texture, and structure of conventional steak.
Develops 3D bioprinters and bioinks for tissue engineering and drug discovery, enabling the creation of 3D biological structures like skin and bone.
Organovo develops 3D printed human tissues to revolutionize drug discovery and medical research.
Develops hybrid modular 3D bioprinters (INVIVO series) and AI-powered organ regeneration platforms for chronic disease treatment, enabling multi-material extrusion with filament, syringe, and hot melt systems.
A global leader in high-precision 3D microfabrication, providing laser-based 3D printers that enable sub-micrometer resolution for industrial and scientific applications.
Pioneer in 3D-printed cultivated meat technology, developing sustainable protein alternatives using proprietary 3D bioprinting and bioink systems for plant-based and cell-based structured meat products.
3D printed bioresorbable breast implants enabling natural tissue regeneration after cancer
A global leader in regenerative medicine that leverages proprietary 3D bioprinting technology to develop bioresorbable medical devices, tissue-derived bio-inks, and cell-based therapeutics.
Inventia Life Science develops world-leading bioprinting technology for advanced medical research, enabling 3D cell culture and tissue engineering applications.
A clinical-stage biotechnology company developing mRNA-based cellular reprogramming technologies and 3D-bioprinted human organs for regenerative medicine.
Supplies high-volume, well-characterized adult human mesenchymal stem cells (hMSCs) and engineered media systems for bioprinting and regenerative medicine, reducing cell costs from >$1,000 to <$10 per million cells.
A pioneering regenerative medicine company specializing in biological additive manufacturing, specifically the world's first 3D bioprinted stem cell vascular grafts (REVOVAS) and proprietary 'Biosynsphere' bio-ink technology.
Develops 3D-bioprinting and materials technologies for regenerative medicine, precision manufacturing patient-specific living tissues and implants.
The Regenova 3D bioprinter enables the creation of three-dimensional living tissue constructs using the innovative Kenzan method, which arranges cell spheroids onto needles for scaffold-free tissue construction.
Embody developed collagen-based regenerative matrices for soft tissue repair using advanced biofabrication.
Developing 3D-bioprinted living implants and resorbable surgical meshes to repair or replace damaged human tissues.
A regenerative and aesthetic medicine company developing innovative 3D bioprinting technologies and products based on proprietary plant-derived recombinant human collagen (rhCollagen) for tissue regeneration, organ manufacturing, and medical aesthetics.
Develops and manufactures patient-specific, resorbable bone implants using a proprietary 3D printing technology that are replaced by the patient's own bone over time.
Develops a 4D biofabrication platform for transplantable tissues and organs, combining cell expansion, biomaterials, and printing technology, with initial focus on corneal grafts for ophthalmology.
Develops a protein-based artificial retina using a layer-by-layer additive manufacturing process in microgravity to restore vision for patients with retinal degenerative diseases like retinitis pigmentosa and age-related macular degeneration.
Develops and supplies recombinant laminin-based cell culture matrices and bioinks for 3D bioprinting and stem cell research, enabling biologically relevant 3D cell culture environments.
Develops high-standard collagen-based medical devices and bioprinting materials for tissue regeneration.
Develops patented 3D-Painting biomaterials platform and rapid-manufacturing process for creating 3D-printed implants for tissue repair, regeneration, and organ restoration; commercializes FDA-cleared CMFlex™ synthetic bone graft using bioprinting technology.
Develops high-purity bio-inks and extracellular matrix materials for 3D bioprinting and tissue engineering applications, enabling reproducible cell culture and research.
Develops 3D bioprinted vascularized organ-on-a-chip models (h-VIOS platform) using hydrogels and human cells for preclinical drug testing, reducing reliance on animal models and accelerating drug discovery timelines.
Develops 3D bioprinting technology to create patient-specific human hearts for transplantation, using the patient's own cells to eliminate organ rejection and reduce transplant waiting lists.
Distributes 3D bioprinters and scientific lab equipment for research and industrial laboratories, providing consultation and technical support.
Develops and manufactures 3D-printed resorbable calcium phosphate scaffolds and bone cements for patient-specific bone regeneration implants, enabling minimally invasive treatment of bone defects.
Biotechnology company developing photopolymer-based 3D bioprinting systems (Print to Perfusion) for manufacturing vascularized, transplantable human organs with patient-derived stem cells, plus five FDA-approved drugs for pulmonary hypertension and oncology
A high-tech biotechnology firm specializing in the industrialization of Bio-3D printing and human-engineered extracellular matrix (hEECM) materials for regenerative medicine and medical aesthetics.
A complete ceramic additive manufacturing solution provider offering high-precision DLP, DIW, and SLA ceramic 3D printers with proprietary materials, software, and sintering processes for research and industrial applications.
Develops an automated 3D bioprinting platform with integrated machine learning co-pilots to standardize human tissue fabrication for pharmaceutical drug screening.
Food tech company using 3D bioprinting and robotics to produce industrial-scale plant-based and hybrid protein products
Develops and manufactures medical-grade Collagen Type 0 derived from jellyfish for bioprinting and tissue engineering, addressing risks of traditional mammalian sources.
Develops a 4D bioprinting suite to produce biocompatible, full-thickness human corneas using iPSC-derived cells to address the global shortage of donor corneas.
A high-resolution 3D screen printing and bioprinting technology company that designs, develops, and manufactures advanced solutions for medical, life science, and cosmetic applications using gentle additive manufacturing processes.
Develops 3D bioprinted hydrogel substrates (Bio-Blocks) for tissue-mimetic cell culture, eliminating subculture to accelerate research and therapeutic development.
3D printed plant-based salmon pioneer, first to sell 3D printed food in supermarkets (rebranded to Revo Foods)
Bioprinting company using Sound Induced Morphogenesis to create skin tissue for wound healing
Develops 3D bioprinted living tumor models from patient-derived cells to accelerate oncology drug discovery and personalized medicine.
Manufactures high-quality collagen fibers at commercial scale using a patented dry-spinning process for tissue engineering, 3D cell culture, and bioprinting applications.
Material Extrusion (Fused Deposition Modeling, FDM; Fused Filament Fabrication, FFF) — a heated thermoplastic filament is extruded through a nozzle, building parts layer by layer.
Based on funding data tracked by AMPulse as of 2026-05, the top Material Extrusion companies include Lonza, GOOD Meat – Eat Just, Redwire, Ourobionics, and Volumetric. Full list of 50 tracked companies available on this page.
Material Extrusion commonly works with PLA, PETG, ABS, PEEK, PEI, nylon, polycarbonate, composites.
Primary applications for Material Extrusion include prototyping, jigs and fixtures, end-use polymer parts, consumer products, education.